Valneva and Pfizer Present P-II (VLA15-221) Study Data of VLA15 Vaccine for Lyme Disease
Shots:
- The P-II (VLA15-221) trial assessed VLA15 vs PBO in pediatric participants (5-17yrs.). A total of 560 healthy participants received either VLA15 (180µg) in two schedules (mos.0-2-6 or mos.0-6) or PBO
- Study showed a strong anamnestic antibody response in all 6 serotypes among individuals (5-65yrs.) & over 90% seroconversion rates 1mos. after the second booster. Geometric Mean Titers were comparably high after both the 1st & 2nd boosters
- The P-III (VALOR) trial of VLA15 in subjects (≥5yrs.) across the US & EU has begun, with primary vaccination series concluded in Jul 2024. Another P-III (VLA15-1012) trial focusing on pediatric safety is underway. Pfizer will submit BLA & MAA to the US FDA & EMA in 2026, based on P-III results
Ref: Valneva | Image: Valneva and Pfizer
Related News:- Valneva Reports EMA Acceptance of VLA1553 for Chikungunya
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
